Precision medicine company IDEAYA Biosciences, Inc. (IDYA) announced Thursday that it has expanded its clinical trial collaboration and supply agreement with pharma major Pfizer Inc. (PFE) for an IDEAYA sponsored clinical combination study of IDE196, a Protein Kinase C (PKC) inhibitor, and crizotinib, a cMET inhibitor to which Pfizer has exclusive worldwide rights.
from RTT - Biotech https://ift.tt/3mLvZUd
via IFTTT
No comments:
Post a Comment